Small Molecules
6 January 2016
Sun BioPharma, Inc. Announces Dosing of First Patient in Phase 1 Clinical Study of SBP-101 for Pancreatic Cancer6 January 2016
Vtesse, Inc. Announces FDA’s Granting of Breakthrough Therapy Designation for VTS-270 in Niemann-Pick Type C1 Disease6 January 2016
eFFECTOR Therapeutics Initiates Dosing in Phase 1/2 Clinical Trial of eFT508 in Solid Tumors6 January 2016
DURECT Announces Positive Phase 1 Data for DUR-9286 January 2016
Sensorion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-2185 January 2016
Relmada Therapeutics Successfully Completes Multiple Ascending Dose Study of d-Methadone for Neuropathic Pain5 January 2016
Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials5 January 2016
Akebia Initiates Phase 3 PRO2TECT™ Program5 January 2016
Cytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy31 December 2015
Epizyme Announces First Patient Dosed in Global Clinical Program Evaluating Tazemetostat in Genetically Defined Solid Tumors30 December 2015
Camurus AB: Braeburn Pharmaceuticals and Camurus Enroll First Patient in a Phase 3 Efficacy Trial of Long-Acting Treatment for Opioid Dependence29 December 2015
Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Diffuse Large B-cell LymphomaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports